Jiangxi Synergy Pharmaceutical 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zhengwei Pang

최고 경영자

CN¥916.8k

총 보상

CEO 급여 비율	n/a
CEO 임기	19.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	13.8yrs
이사회 평균 재임 기간	6.9yrs

최근 관리 업데이트

Recent updates

Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock Rockets 43% But Many Are Still Ignoring The Company

Oct 08

Is Jiangxi Synergy Pharmaceutical (SZSE:300636) A Risky Investment?

Jun 28

Jiangxi Synergy Pharmaceutical's (SZSE:300636) Profits Appear To Have Quality Issues

May 01

Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) 41% Share Price Surge Not Quite Adding Up

Apr 27

CEO

Zhengwei Pang (62 yo)

19.6yrs

테뉴어

CN¥916,800

보상

Mr. Zhengwei Pang has been the Chairman and General Manager of Jiangxi Synergy Pharmaceutical Co., Ltd. since April 2005.

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhengwei Pang	Chairman & GM	19.6yrs	CN¥916.80k	데이터 없음
Zhongcheng Liang	Vice Chairman & Deputy GM	9.8yrs	CN¥667.80k	데이터 없음
Jinqiao Hu	Financial Director	9.8yrs	CN¥369.00k	0.031% CN¥ 1.1m
Yuansen Jiang	Deputy GM & Director	13.8yrs	CN¥672.60k	1.26% CN¥ 44.2m
Guojun Huang	Deputy GM & Director	9.6yrs	CN¥674.20k	0.38% CN¥ 13.3m
Zhicheng Zhou	Deputy GM & Secretary of the Board	10.7yrs	CN¥614.40k	0.18% CN¥ 6.3m
Aicheng Ma	Supervisor & Chief Dispatcher of Production Technology Department	20.8yrs	데이터 없음	데이터 없음

13.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 300636 의 관리팀은 노련하고 경험 (평균 재직 기간 13.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhengwei Pang	Chairman & GM	19.6yrs	CN¥916.80k	데이터 없음
Zhongcheng Liang	Vice Chairman & Deputy GM	9.8yrs	CN¥667.80k	데이터 없음
Yuansen Jiang	Deputy GM & Director	13.8yrs	CN¥672.60k	1.26% CN¥ 44.2m
Guojun Huang	Deputy GM & Director	9.6yrs	CN¥674.20k	0.38% CN¥ 13.3m
Aicheng Ma	Supervisor & Chief Dispatcher of Production Technology Department	9.8yrs	데이터 없음	데이터 없음
Hong Wan	Independent Director	2.5yrs	CN¥60.00k	데이터 없음
Shaojiong Yu	Supervisory Board Chairman	6.5yrs	데이터 없음	0.13% CN¥ 4.4m
Guoping Li	Independent Director	3.6yrs	CN¥60.00k	데이터 없음
Huigang Jiang	Non-Independent Director	6.5yrs	CN¥401.40k	0.025% CN¥ 867.6k
Xiaohua Wang	Non-Independent Director	7.3yrs	CN¥434.10k	0.054% CN¥ 1.9m
Xin Peng	Independent Director	3.6yrs	CN¥60.00k	데이터 없음
Qingyuan He	Employee Representative Supervisor	3.6yrs	데이터 없음	데이터 없음

6.9yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: 300636 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.

Jiangxi Synergy Pharmaceutical 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Jiangxi Synergy Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.054 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock Rockets 43% But Many Are Still Ignoring The Company

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.068 in 2Q 2023)

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Is Jiangxi Synergy Pharmaceutical (SZSE:300636) A Risky Investment?

Jiangxi Synergy Pharmaceutical's (SZSE:300636) Profits Appear To Have Quality Issues

Jiangxi Synergy Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2023

Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) 41% Share Price Surge Not Quite Adding Up

Jiangxi Synergy Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.054 (vs CN¥0.094 in 3Q 2022)

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.05 in 2Q 2022)

Jiangxi Synergy Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023

First quarter 2023 earnings released: EPS: CN¥0.095 (vs CN¥0.087 in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.094 (vs CN¥0.078 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.072 in 2Q 2021)

Jiangxi Synergy Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 05 July 2022

Investor sentiment deteriorated over the past week

Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Final Dividend for 2021

Jiangxi Synergy Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.091 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.13 in 2Q 2020)

Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 02, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.56

New 90-day low: CN¥22.14

New 90-day low: CN¥26.06

New 90-day low: CN¥28.54

New 90-day low: CN¥31.21

Third quarter earnings released

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Earnings released

Jiangxi Synergy Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령